Aurobindo Pharma (APL) has chalked out an investment plan of Rs 1,250 crore
to be implemented by 2015.
APL is likely to have a cash flow of Rs 800 crore. Of this, Rs 250 crore will
be utilised for capital expenditure and Rs 150 crore towards working capital
margin. The remaining Rs 400 crore will be free cash flow to be utilised for
funding the redemptions (if any) of foreign currency convertible bonds over the
next two years.
At present, APL is constructing a separate block for production of oral
contraceptives at cost of Rs 60 crore at its facility in the SEZ near Jadcherla
in Andhra Pradesh. The proposed facility is slated to be ready by June 2011.
In March 2010, APL launched AuroSource, its new Rs 100-crore division for
providing custom research and manufacturing services.